Top Abstract Purchase Related
Home
>
Node
>
Subnode

Histoculture drug response assay guided concurrent chemoradiotherapy for non-small cell lung cancer

Tamaki, T.; Oura, S.; Yoshimasu, T.; Ota, F.; Nakamura, R.; Shimizu, Y.; Kiyoi, M.; Naito, K.; Hirai, Y.; Okamura, Y.

Kyobu Geka. Japanese Journal of Thoracic Surgery 61(1): 31-35

2008

ISSN/ISBN: 0021-5252
PMID: 18186270
Document Number: 619300
Retrospective analysis was done to evaluate concurrent chemoradiotherapy (CCRT) using chemotherapeutic agents judged to be sensitive by histoculture drug response assay (HDRA) for non-small cell lung cancer (NSCLC). We treated 21 NSCLC patients with CCRT using senstivie agents judged by HDRA from 1999 to 2004. Objective response was evaluated in 20 patients. They were consisted of 1 complete response (CR) case, 18 partial response (PR) cases, and 1 stable disease (SD) case. The response rate was 95%. Ten cancer related deaths were observed during 816 +/- 861 (60-2,780) days follow-up. Median survival time was 604 days. One- and 5-year survival rates were 73.9% and 40.3%, respectively. In conclusion, HDRA may improve efficacy of CCRT for NSCLC.

Document emailed within 1 workday
Secure & encrypted payments

Tanahashi, M.; Yamada, T.; Moriyama, S.; Suzuki, E.; Niwa, H. 2008: The effect of the histoculture drug response assay (HDRA) based perioperative chemotherapy for non-small cell lung cancer Kyobu Geka. Japanese Journal of Thoracic Surgery 61(1): 26-30
Hou, H.-l.; Hao, J.-l.; Pang, Q.-s.; Wang, P. 2010: Concurrent chemoradiotherapy for stage IIi non-small cell lung cancer Zhonghua Yi Xue Za Zhi 90(29): 2068-2070
Turrisi, A.T. 1997: Concurrent chemoradiotherapy for limited small-cell lung cancer Oncology 11(9 Suppl 9: 31-37
Tamura, A.; Mikami, A.; Sagara, Y.; Hebisawa, A. 2000: Concurrent chemoradiotherapy using a single agent for unresectable stage IIi non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(11): 1755-1758
Rusch, V.W.; Albain, K.S.; Crowley, J.J.; Rice, T.W.; Lonchyna, V.; McKenna, R.; Livingston, R.B.; Griffin, B.R.; Benfield, J.R. 1993: Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial Journal of Thoracic and Cardiovascular Surgery 105(1): 97
Lee, H-W.; Choi, J-H.; Lim, H-Y.; Park, J.S.; Kim, H.C.; Kang, S.; Oh, Y.T.; Chun, M.; Sheen, S.S.; Oh, Y.J.; Park, K.J.; Hwang, S.C. 2006: The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis Neoplasma 53(1): 30-36
Tanino, H.; Miyoshi, S.; Furukawa, T.; Bessho, T.; Maebeya, S.; Suzuma, T.; Hirai, I.; Arimoto, J.; Harada, N.; Hoso, T.; Naito, Y. 1997: Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer--a case report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 24(7): 861-864
Fujimoto, H.; Oyama, T.; Suito, T.; Hashimoto, K.; Kameyama, Y.; Yasuda, H.; Ishizuka, H. 2010: A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(2): 295-298
Furukawa, T.; Kubota, T.; Tanino, H.; Oura, S.; Yuasa, S.; Murate, H.; Morita, K.; Kozakai, K.; Yano, T.; Hoffman, R.M. 2000: Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay Anticancer Research 20(5c): 3657-3658
Yoshimasu, T.; Oura, S.; Hirai, I.; Kokawa, Y.; Okamura, Y.; Furukawa, T. 2005: Dose response curve of paclitaxel measured by histoculture drug response assay Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(4): 497-500
Hoffman, R.M. 2000: The clinical benefit of the histoculture drug response assay Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 321-322
Sanada, H.; Hayashi, A.; Tomimitsu, S.; Ikeda, K.; Nakanishi, K.; Hiyama, J.; Hidaka, D.; Sawamoto, R.; Miyagawa, Y.; Misumi, Y.; Fujii, A.; Nakatsubo, S.; Tsuru, M.; Omagari, J.; Koshizuka, H. 2009: Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(12): 2012-2015
Iatsenko, L.D. 2007: Results of palliative chemoradiotherapy of advanced small cell lung cancer using polyplatillen Likars'ka Sprava 3: 39-42
Cihan, Y.B. 2014: Do trace element levels have prognostic value in non-small cell lung cancer patients treated with chemoradiotherapy? Journal of Buon: Official Journal of the Balkan Union of Oncology 19(3): 749-756
Niho, S.; Motegi, A.; Akimoto, T. 2015: Proton beam therapy with concurrent chemotherapy for non-small cell lung cancer -- our experiences and future direction Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(2): 144-147
Fujii, S.; Hamamoto, Y.; Sugai, Y. 1993: Concurrent daily low-dose cisplatin combined with chest irradiation in advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(10): 1397-1399
Tell, R.; Sederholm, C.; Klintenberg, C.; Franksson, L.; Brandén, E.; Hillerdal, G.; Lönn, U.; Lindén, C.-J.; Ewers, S.-B.ör.; Lamberg, K.; Mrazek, E.; Lödén, B.; Sjögren, A.; Linné, T.; Friesland, S.; Sirzén, F. 2008: Multicentre phase Ii trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer Anticancer Research 28(5b): 2851-2857
Saxena, A.; Nagasaka, M.; Li, Z.; Becker, D.J.; Levy, B.P. 2014: Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer Oncology 28(6): 526; 528 530, 534
Neill, H.B.; Miller, A.A.; Clamon, G.H.; Perry, M.C.; Crawford, J.; Green, M.R. 1997: A phase Ii study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer Seminars in Oncology 24(4 Suppl 12: S12
2016: (S040) Nadir White Blood Cell, Absolute Neutrophil, and Absolute Lymphocyte Counts During Concurrent Chemoradiation Therapy Predicted Worse Outcomes in Patients With Limited-Stage Small-Cell Lung Cancer Oncology 30 Suppl